3 news items
ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M
ABVC
26 Mar 24
as the R&D partner of ForSeeCon to discover new pipelines for ophthalmic products. From better vitreous substitutes to various eyecare products, our
ABVC BioPharma Provides Fiscal Year 2024 Q1 Business Update
ABVC
14 Mar 24
and $85,265, respectively. Recent R&D Operational Highlights
ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update
ABVC
14 Mar 24
. Recent R&D Operational Highlights Patents and FDA
- Prev
- 1
- Next